Delphia (USA)’s Vor Biopharma VOR Stock Holding History

Delphia (USA)’s Portfolio VOR Stock Details VOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-807	Closed	-$80K	–	425
2022 Q2	$80K	Buy	+807	New	+$82.6K	0.06%	358

Other funds holding VOR

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Fidelity Investments

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Delphia (USA)'s VOR Position: Q3 2022 in Review

Delphia (USA) sold out of Vor Biopharma (VOR) in Q3 2022, closing a stake of 807 shares — an estimated $80K sold.

Delphia (USA) first reported a position in VOR in Q2 2022 and held it in 1 quarter. The position peaked at $80K in Q2 2022. 48 funds tracked by Wall St. Rank hold VOR as of Q3 2022.

Delphia (USA) reported no remaining Vor Biopharma position as of Q3 2022 after selling out during the quarter.
Delphia (USA) sold 807 Vor Biopharma shares in Q3 2022, an estimated $80K.
Delphia (USA) first reported a position in Vor Biopharma in Q2 2022 and held it in 1 quarter.
Delphia (USA)'s Vor Biopharma position peaked at $80K in Q2 2022.
48 funds tracked by Wall St. Rank held Vor Biopharma as of Q3 2022.

Based on Delphia (USA)'s 13F filing for Q3 2022, filed 14 Nov 2022.